IONS - Pfizer launches Phase 2b vupanorsen study in patients with elevated cholesterol level

Pfizer (PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-L) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), says Ionis Pharmaceuticals (IONS) and its subsidiary Akcea Therapeutics (AKCA).The study, Targeting ANGPTL3 with an antisense oligonucleotide in adults with dyslipidemia (TRANSLATE-TIMI 70), will evaluate various doses of vupanorsen to inform potential future development. The first patient has been treated in the placebo-controlled, dose-ranging Phase 2b study. The trial is expected to enroll 260 participants (? 40 years old) and will assess the efficacy, safety, tolerability and pharmacokinetics of vupanorsen, and the primary endpoint is percent change from baseline in non-HDL-C at week 24. In November 2019, Akcea and Ionis announced the closing of a worldwide exclusive licensing agreement with Pfizer for vupanorsen. Under the terms of the deal, the initiation of the Phase 2b study triggered a milestone payment of $75M from Pfizer. Vupanorsen is an

For further details see:

Pfizer launches Phase 2b vupanorsen study in patients with elevated cholesterol level